UNSPSC 51141560: Etiracetam

This classification denotes an anticonvulsant agent with the molecular formula C8H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 230447L0GL, chemically known as 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-, (s)- but generally known as etiracetam, which bears US NIH Compound Identifier 59708. European Medicines Agency schedules Etiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07308MIG.

UNSPSC 51141560 Etiracetam is a Commodity code that in recent state and local procurement activity encompasses pharmaceutical products and related supply-chain services. The recent opportunities tagged to this code show a divergence: the code nominally identifies a specific nootropic compound (piracetam's analog), yet the sourced solicitations span naloxone procurement, direct-to-manufacturer pharmacy initiatives, and multi-source generic pharmaceutical contracting — none of which are etiracetam specifically. State and local governments are using this code to solicit pharmaceutical products, drug-deactivation systems, and pharmacy benefit program services through RFPs, RFQs, and RFI mechanisms. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across participating jurisdictions including Oregon). The scope encompasses both direct product procurement—naloxone units and over-the-counter pharmaceuticals with specific National Drug Codes—and strategic pharmacy-services contracting focused on cost management and prescription fulfillment efficiency.

Recent activity spans Florida, Texas, and Minnesota-led multi-state participation. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 (due July 26, 2023, per the source timeline), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and fixed-fee pricing; vendors must comply with E-Verify, workers' compensation insurance, and potential FEMA compliance requirements including the Clean Air Act. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, requesting vendor experience with self-insured employer contracting and value-based pricing models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent on administrative compliance, and awarded vendors effective July 1, 2026. The code shows limited recent activity closely aligned with its nominal scope; bidders should verify that etiracetam-specific opportunities exist before pursuing under this classification.